Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 82
Steady prescription uptake for SaxendaⓇ in the US
Prescription volume uptake of anti-obesity
medications (AOM) recently launched in the US
TRX
Volume (000)
80
70
60
50
40
30
20
10-
0
ContraveⓇ
QsymiaⓇ
BelviqⓇ
SaxendaⓇ
55
39
35
•
18
Key observations
SaxendaⓇ has been launched in 15 markets, including the
US, Canada, Denmark, Italy, Australia, Mexico, Germany,
Belgium, Brazil, Israel and now Sweden, the Netherlands,
Spain, UAE, and Russia
SaxendaⓇ is the leader in value market share at ~49%
among branded AOM in the US
While competitors have recently reduced their promotional
efforts, Novo Nordisk remains confident in the long-term
obesity market growth and the evolving Novo Nordisk
obesity portfolio
Aug
2015
Source: IMS NPA TRX, monthly, August 2016
changing
diabetes®
Aug
2016
Source: IMS NSP, Monthly data, August 2016
novo nordiskView entire presentation